Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cancer vaccines: Targeting KRAS-driven cancers.

Expert review of vaccines - 1 Feb 2020

Zhang Ying, Ma Jin-An, Zhang Hai-Xia, Jiang Yu-Na, Luo Wen-Hao

Abstract excerpt

Introduction: Mutant KRAS is a genetic driver of multiple cancers that has challenged clinical anti-cancer therapeutics in the last 3 decades. Neo-antigens encoded by KRAS mutations have been identified as tumor-specific with high immunogenicity and can be used to deliver precision cancer vaccines to promote anti-tumor immune responses. KRAS mutation-based cancer vaccines have produced encouraging preclinical and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Vaccines
Share to Immunogenicity, Vaccine
Share to Mutation

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Neoplasms

Share to Proto-Oncogene Proteins p21(ras)

Share to Tumor Microenvironment

Source

Identifiers

PMID: 32174221
DOI: 10.1080/14760584.2020.1733420

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cancer vaccines: Targeting KRAS-driven cancers.PMID 32174221Read ↗

Preclinical development of a mutant KRAS targeting therapeutic cancer vaccine.Semantic proximity Read ↗

Targeting KRAS in colorectal cancer immunotherapy: rationale, challenges and future directions.Semantic proximity Read ↗

Targeting the undruggable oncogenic KRAS: the dawn of hope.Semantic proximity Read ↗

GI-4000 in KRAS mutant cancers.Semantic proximity Read ↗

Drugging the undruggable: Advances in targeting KRAS signaling in solid tumors.Semantic proximity Read ↗

KRAS G12C inhibition and innate immune targeting.Semantic proximity Read ↗

KRAS Mutations in Cancer: Understanding Signaling Pathways to Immune Regulation and the Potential of ImmunotherapySemantic proximity Read ↗

Unveiling the role of KRAS in tumor immune microenvironment.Semantic proximity Read ↗

Immune modulatory effects of oncogenic KRAS in cancerSemantic proximity Read ↗

Targeting the KRAS Oncogene for Patients with Metastatic Colorectal CancerSemantic proximity Read ↗

A lentiviral vector targeting a KRAS neoepitope for cancer immunotherapySemantic proximity Read ↗

Systematic discovery and validation of T cell targets directed against oncogenic KRAS mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.